Matthew Call, DO
Rheumatology · Springville, UTNPI 1083904619
Payments from drug & device makers
Across 1,140 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AbbVie$2K
- Johnson & Johnson$2K
- UCB, Inc.$2K
- Pfizer$1K
- Novartis$1K
- plus $5K from 28 others
What the payments were for
- Food & beverage$16,97697%
- Education$5223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 265 | $4,131 |
| AbbVie | 138 | $2,231 |
| Johnson & Johnson | 75 | $1,668 |
| UCB, Inc. | 82 | $1,594 |
| Pfizer | 197 | $1,428 |
| Novartis | 67 | $1,335 |
| Lilly USA, LLC | 81 | $1,241 |
| AstraZeneca | 40 | $738 |
| E.r. Squibb & Sons, L.L.C. | 34 | $504 |
| GSK | 28 | $486 |
| Genentech USA, Inc. | 23 | $363 |
| Organon | 30 | $352 |
| Kiniksa Pharmaceuticals, Ltd. | 8 | $195 |
| Bristol Myers Squibb | 12 | $153 |
| Fresenius Kabi USA, LLC | 8 | $143 |
| Merck | 11 | $143 |
| Gilead | 7 | $133 |
| Boehringer Ingelheim | 6 | $103 |
| Sandoz | 4 | $71 |
| Collegium Pharmaceutical, Inc. | 4 | $68 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $66 |
| Sanofi | 3 | $64 |
| Genentech, Inc. | 1 | $50 |
| Aurinia Pharma U.S., Inc. | 2 | $44 |
| Sobi, Inc | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Mylan Institutional Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Biocon Biologics Inc | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$106
How this compares
$17,498 in reported general payments places this provider in the 75th percentile of 52 rheumatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 14 | $99,636 |
| ForteoTeriparatide | 21 | $95,570 |
| OtezlaApremilast | 11 | $53,202 |
| Hydroxychloroquine Sulfate | 711 | $26,790 |
| Celecoxib | 375 | $12,080 |
| MethotrexateMethotrexate Sodium | 460 | $8,926 |
| Leflunomide | 141 | $6,269 |
| Colchicine | 132 | $6,099 |
| Mycophenolate Mofetil | 16 | $2,721 |
| Mycophenolic AcidMycophenolate Sodium | 14 | $2,634 |
| Pregabalin | 151 | $2,499 |
| Duloxetine Hcl | 77 | $1,733 |
| Folic Acid | 172 | $1,722 |
| Azathioprine | 32 | $1,510 |
| Methocarbamol | 55 | $1,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $1,241 | $95,57021 claims |
| AmgenOtezla | $4,131 | $53,20211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 52 rheumatology providers in Utah.
Other rheumatology in Springville
- Jessica WalshSlc$1.4M
- Catherine BakewellSalt Lake City$1.2M
- Brayden YellmanMurray$452K
- Grant CannonSalt Lake City$187K
- Shruti SanghviVineyard$63K
- Curry KoeningSalt Lake City$63K
- Carmen GotaSt. George$56K
- Gopi PenmetsaSalt Lake City$39K
- Ryan HogganLayton$36K
- Dany SaadMurray$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.